Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report
Open Access
- 24 March 2020
- journal article
- case report
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 13 (1) , 304-308
Abstract
A 49-year-old woman with ER-positive/PR-negative/HER2-negative metastatic breast cancer experienced Grade 3 hepatotoxicity following initiation of a clinical trial of fulvestrant, palbociclib, and erdafitinib. Fulvestrant was determined to be the drug most likely responsible for this hepatotoxic effect. This case report details the timing and nature of this drug-induced liver injury, adding support to an area that has yet to be described adequately in the existing literature.Keywords
This publication has 6 references indexed in Scilit:
- A Rare Case of Fulvestrant-Associated Jaundice and HepatotoxicityAmerican Journal of Therapeutics, 2019
- Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast CancerJNCI: Journal of the National Cancer Institute, 2018
- Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumorsInvestigational New Drugs, 2017
- Pseudocirrhosis and liver failure in patients with metastatic breast cancer after treatment with palbociclibHepatology, 2016
- Hepatotoxicity Secondary to ChemotherapyJournal of Clinical and Translational Hepatology, 2014
- DRUG-INDUCED LIVER DISEASEClinics in Liver Disease, 2000